- Trials with a EudraCT protocol (68)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
68 result(s) found for: Brain ischemia.
Displaying page 1 of 4.
EudraCT Number: 2009-009505-25 | Sponsor Protocol Number: Xe-Hypotheca | Start Date*: 2009-03-18 | ||||||||||||||||
Sponsor Name:Timo Laitio | ||||||||||||||||||
Full Title: Effect of Xenon, in Combination with Therapeutic Hypothermia, on the Brain and on Neurological Outcome following Brain Ischemia in Cardiac Arrest Patients | ||||||||||||||||||
Medical condition: Sydänpysähdyksen jälkeinen globaali iskemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000702-19 | Sponsor Protocol Number: LITE | Start Date*: 2015-07-22 | ||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||
Full Title: Haemostatic and Fibrinolytic Analysis of Low Molecular Weight Heparin Injections versus Unfractionated Heparin Infusion as Post-CABG Thromboprophylaxis | ||||||||||||||||||
Medical condition: Deep venous thrombosis, myocardial infarction, cerebral infarction, bleeding | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001581-20 | Sponsor Protocol Number: IRRB/72/14 | Start Date*: 2018-02-08 | |||||||||||||||||||||
Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT | |||||||||||||||||||||||
Full Title: THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENT... | |||||||||||||||||||||||
Medical condition: ISCHEMIC REPERFUSION INJURY AFTER LIVER TRANSPLANTATION: HEPATIC ISCHEMIA AND REPERFUSION INJURY REPRESENTS THE MAIN UNDERLYING MECHANISM FOR GRAFT DYSFUNCTION, AND FAILURE, POST-TRANSPLANTATION. H... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000790-79 | Sponsor Protocol Number: 2018-000790-79 | Start Date*: 2021-08-09 |
Sponsor Name:Academic Medical Centre Amsterdam | ||
Full Title: IMPROVING OUTCOME IN SUBARACHNOID HEMORRHAGE WITH NADROPARINE | ||
Medical condition: Patients suffering from an aneurysmal subarachnoid hemorrhage. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001620-33 | Sponsor Protocol Number: APHP200033 | Start Date*: 2021-01-13 |
Sponsor Name:ASSISTANCE-PUBLIQUE HOPITAUX DE PARIS (AP-HP) | ||
Full Title: HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome | ||
Medical condition: Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002708-25 | Sponsor Protocol Number: RIVAROXACS3001 (BAY59-7939/13194) | Start Date*: 2008-11-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 ... | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) DE (Completed) PT (Completed) SK (Completed) HU (Completed) FR (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) IT (Completed) LV (Completed) CZ (Completed) BG (Completed) BE (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001322-54 | Sponsor Protocol Number: CS/2018/6632 | Start Date*: 2020-06-15 | ||||||||||||||||||||||||||
Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Brain injury during open heart valve surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004180-43 | Sponsor Protocol Number: BAY59-7939/15786 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People u... | |||||||||||||
Medical condition: Prevention of major cardiovascular events in patients with coronary or peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) CZ (Completed) FI (Completed) IT (Completed) HU (Completed) NL (Completed) GB (Completed) SK (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003959-22 | Sponsor Protocol Number: CV006-004 | Start Date*: 2016-09-06 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acet... | ||||||||||||||||||
Medical condition: Recurrent Brain Infarction in Subjects receiving acetylsalicyl acid (ASA) following Acute Ischemic Stroke or Transient Ischemic Attack | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003050-41 | Sponsor Protocol Number: HJE-PHARMA-001 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Efficacy of GLP-1 agonists and restrictive vs. liberal FiO2 in patients undergoing coronary artery bypass grafting or aortic valve replacement – a 2-by-2 factorial designed, randomized clinical study | |||||||||||||
Medical condition: We investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replaceme... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005029-19 | Sponsor Protocol Number: CV010031 | Start Date*: 2020-06-09 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc... | ||||||||||||||||||
Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002151-10 | Sponsor Protocol Number: NEUROPROTECTpost-CA | Start Date*: 2015-08-07 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial) | |||||||||||||
Medical condition: post-cardiac arrest patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001617-32 | Sponsor Protocol Number: MINOR | Start Date*: 2013-12-05 |
Sponsor Name:AUSL di Piacenza | ||
Full Title: Thrombolysis in Minor Stroke | ||
Medical condition: The condition to be treated is the stroke of “minor” grade (National Institutes of Health Stroke Scale (NIHSS) score < 5). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002006-27 | Sponsor Protocol Number: CKJX839B12302 | Start Date*: 2021-11-15 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease... | |||||||||||||
Medical condition: Atherosclerotic cardiovascular disease (ASCVD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) IS (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008319-24 | Sponsor Protocol Number: AGO/2008/015 | Start Date*: 2009-02-17 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: A single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation. | |||||||||||||
Medical condition: Cirrhotic patients receiving a primary liver transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001185-41 | Sponsor Protocol Number: POINT | Start Date*: 2013-11-26 | ||||||||||||||||
Sponsor Name:University of California San Francisco Stroke Sciences Group | ||||||||||||||||||
Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial | ||||||||||||||||||
Medical condition: Transient Ischemic Attack and Minor Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000061-21 | Sponsor Protocol Number: I1V-MC-EIAN | Start Date*: 2012-10-25 | ||||||||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||||||||||||
Full Title: Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study | ||||||||||||||||||||||||||||
Medical condition: High Risk Vascular Disease (HRVD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) SK (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005731-67 | Sponsor Protocol Number: NLxxxxxxxxxx | Start Date*: 2021-07-02 | |||||||||||
Sponsor Name:Haaglanden Medisch Centrum | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1 esterase inhibitor for the acute management of subar... | |||||||||||||
Medical condition: Subarachnoid hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006067-31 | Sponsor Protocol Number: NTI-ASP-0503 | Start Date*: 2008-04-04 |
Sponsor Name:Neurobiological Technologies Inc | ||
Full Title: ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hou... | ||
Medical condition: Acute Ischemic Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001960-31 | Sponsor Protocol Number: S54348 | Start Date*: 2013-05-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study | ||
Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
